Inventor · disambiguated record
Barry A. Springer
Also filed as: SPRINGER BARRY · SPRINGER BARRY A
13 granted patents·5 pending applications·493 citations·filing 1998–2016
92Inventor score
Files withDIMENSIONAL PHARM INC10LEONARD KRISTI A3BONE ROGER F1JACKSON PAUL FRANCIS1JANSSEN PHARMACEUTICA NV1
Top patents by PatentIndex Score
18 records- 0196US6569631B1Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyesDIMENSIONAL PHARM INC·Filed 1999·Granted May 27, 2003·270 cites·12 claims
- 0293US6268158B1Method for determining conditions that facilitate protein crystallizationDIMENSIONAL PHARM INC·Filed 1999·Granted Jul 31, 2001·87 cites·18 claims
- 0391US6291192B1Method for identifying conditions that facilitate recombinant protein foldingDIMENSIONAL PHARM INC·Filed 2000·Granted Sep 18, 2001·28 cites·19 claims
- 0487US6274712B1Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137DIMENSIONAL PHARM INC·Filed 1998·Granted Aug 14, 2001·48 cites·9 claims
- 0585US6737404B2Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137DIMENSIONAL PHARM INC·Filed 2001·Granted May 18, 2004·10 cites·30 claims
- 0680US6232085B1Method for determining conditions that stabilize proteinsDIMENSIONAL PHARM INC·Filed 1999·Granted May 15, 2001·29 cites·43 claims
- 0772US6291191B1Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimizationDIMENSIONAL PHARM INC·Filed 1999·Granted Sep 18, 2001·19 cites·11 claims
- 0870US6767722B1Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, Aspartate 101 or Leucine 137DIMENSIONAL PHARM INC·Filed 2000·Granted Jul 27, 2004·1 cites·29 claims
- 0964US7138374B2Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, asparate 101 or leucine 137DIMENSIONAL PHARM INC·Filed 2004·Granted Nov 21, 2006·0 cites·83 claims
- 1063US8883473B2Methods of treatment using allosteric processing inhibitors for matrix metalloproteinasesLEONARD KRISTI A·Filed 2012·Granted Nov 11, 2014·1 cites·14 claims
- 1150US8798939B2Methods for designing, selecting and/or optimizing allosteric processing inhibitors for matrix metalloproteinasesLEONARD KRISTI A·Filed 2012·Granted Aug 5, 2014·0 cites·4 claims
- 1248US2003175813A1Microplate thermal shift assay for ligand development using 5- (4"-dimethylaminophenyl) -2- (4' -phenyl) oxazole derivative fluorescent dyesDIMENSIONAL PHARM INC·Filed 2003·Application pending·0 cites
- 1346US9815790B2Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Nov 14, 2017·0 cites·33 claims
- 1442US2006094081A1Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallizationSCHUBERT CARSTEN·Filed 2005·Application pending·0 cites
- 1539US2006110732A1Method for the identification of ligandsBONE ROGER F·Filed 2003·Application pending·0 cites
- 1638US8753857B2Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitorLEONARD KRISTI A·Filed 2012·Granted Jun 17, 2014·0 cites·4 claims
- 1738US2012302573A1Methods of inhibiting pro matrix metalloproteinase activationJACKSON PAUL FRANCIS·Filed 2012·Application pending·0 cites
- 1838US2006024844A1Method for the idenification of ligandsRENTZEPERIS DIONISIOS·Filed 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →